59 related articles for article (PubMed ID: 2786553)
21. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
22. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.
Tamura T; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Fujiwara Y; Nakagawa K; Minato K; Bungo M; Saijo N
Cancer Res; 1989 Feb; 49(3):730-5. PubMed ID: 2783385
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-2 and lymphokine activated killer cells: promises and cautions.
Glassman AB
Ann Clin Lab Sci; 1989; 19(1):51-5. PubMed ID: 2644890
[TBL] [Abstract][Full Text] [Related]
28. [Interleukin-2 based immunotherapy of cancer].
Geertsen PF; Hermann GG; Claësson MH; Steven K; Zeuthen J; von der Maase H
Ugeskr Laeger; 1990 Nov; 152(47):3513-7. PubMed ID: 2256204
[TBL] [Abstract][Full Text] [Related]
29. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
Velotti F; Tubaro A; Stoppacciaro A; Pettinato A; Morrone S; Bossola P; Napolitano T; Miano L; Ruco L; Piccoli M
Ann Ist Super Sanita; 1990; 26(3-4):411-21. PubMed ID: 2091503
[TBL] [Abstract][Full Text] [Related]
30. Recombinant interleukin-2: a biological response modifier.
Kintzel PE; Calis KA
Clin Pharm; 1991 Feb; 10(2):110-28. PubMed ID: 2009728
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.
Whittington R; Faulds D
Drugs; 1993 Sep; 46(3):446-514. PubMed ID: 7693434
[TBL] [Abstract][Full Text] [Related]
32. New clinical trials with interleukin-2: rationale for regional administration.
Roth AD; Kirkwood JM
Nat Immun Cell Growth Regul; 1989; 8(3):153-64. PubMed ID: 2674703
[TBL] [Abstract][Full Text] [Related]
33. In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies.
Sosman JA; Hank JA; Sondel PM
Semin Oncol; 1990 Feb; 17(1 Suppl 1):22-30; discussion 38-41. PubMed ID: 2405492
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-2 in cancer therapy.
Parkinson DR
Semin Oncol; 1988 Dec; 15(6 Suppl 6):10-26. PubMed ID: 3061014
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-2: solid-tumor therapy.
Oppenheim MH; Lotze MT
Oncology; 1994; 51(2):154-69. PubMed ID: 8196899
[TBL] [Abstract][Full Text] [Related]
36. The immunotherapy of human cancer with interleukin 2: present status and future directions.
Kolitz JE; Mertelsmann R
Cancer Invest; 1991; 9(5):529-42. PubMed ID: 1933486
[TBL] [Abstract][Full Text] [Related]
37. Effects of route and formulation on clinical pharmacokinetics of interleukin-2.
Anderson PM; Sorenson MA
Clin Pharmacokinet; 1994 Jul; 27(1):19-31. PubMed ID: 7955769
[TBL] [Abstract][Full Text] [Related]
38. Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells.
Mier JW; Aronson FR; Numerof RP; Vachino G; Atkins MB
Pathol Immunopathol Res; 1988; 7(6):459-76. PubMed ID: 2976936
[TBL] [Abstract][Full Text] [Related]
39. Overview of interleukin-2 as an immunotherapeutic agent.
Chang AE; Rosenberg SA
Semin Surg Oncol; 1989; 5(6):385-90. PubMed ID: 2688029
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
